Product Description
PDE4 inhibitor (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567892/)
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inflazyme
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00330070 |
IPL512,602-2002 | P2 |
Completed |
Asthma |
None |
2019-03-21 |
Treatments |